Skip to Main Content

Paper Details

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Clin Cancer Res
98
2018
CHD1, CHD1 protein, CRPC, ERG, HSPC, Lethal Prostate Cancer, PTEN, SPOP, SPOP mutations, castration-resistant prostate cancer, castration-resistant tumor, hormone, hormone-sensitive prostate cancer, mCRPC, metastatic CRPC, patient, patients, prostate cancer, tumors
Author NameAffiliation
Gunther BoysenInstitute of Cancer Research
Zafeiris ZafeiriouThe Royal Marsden NHS Foundation Trust
Raquel Perez-LopezVall D'Hebron Institute of Oncology
Nina TunariuThe Royal Marsden NHS Foundation Trust
Susana MirandaInstitute of Cancer Research
Matthew ClarkeInstitute of Cancer Research
Adam SharpInstitute of Cancer Research
Theresa Y MacDonaldSandra and Edward Meyer Cancer Center
Theresa Y MacDonaldEnglander Institute for Precision Medicine, New York-Presbyterian Hospital
Theresa Y MacDonaldSandra and Edward Meyer Cancer Center
Theresa Y MacDonaldEnglander Institute for Precision Medicine, New York-Presbyterian Hospital
Mark A RubinSandra and Edward Meyer Cancer Center
Mark A RubinUniversity of Bern
Mark A RubinEnglander Institute for Precision Medicine, New York-Presbyterian Hospital
Mark A RubinSandra and Edward Meyer Cancer Center
Mark A RubinEnglander Institute for Precision Medicine, New York-Presbyterian Hospital
Mark A RubinUniversity of Bern
Wei YuanInstitute of Cancer Research
Christopher E BarbieriSandra and Edward Meyer Cancer Center
Christopher E BarbieriNew York-Presbyterian Hospital
Christopher E BarbieriSandra and Edward Meyer Cancer Center
Christopher E BarbieriNew York-Presbyterian Hospital
Suzanne CarreiraInstitute of Cancer Research
Joaquin MateoVall D'Hebron Institute of Oncology
Johann S de BonoInstitute of Cancer Research
Johann S de BonoThe Royal Marsden NHS Foundation Trust
  • 1 - 26

Datasets

Release 1.2